| Efficacy and Safety of Curcumin as an Adjuvant to Standard Chemotherapy in Advanced and Metastatic Breast Cancer Patients: A Randomized Controlled Study 2025 · chemotherapy with oral curcumin · Women with locally advanced or metastatic breast cancer | 1 g | — | 24 weeks | — |
| The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial 2022 · curcumin-piperine group · Adults aged 18–65 with RT-PCR-confirmed COVID-19 who were outpatients and did not have severe disease requiring hospitalization | 1 g | 10 mg | 2 weeks | 23 |
| Randomised Clinical Trial Study: The Combination of Vitamin D and Curcumin Piperine Attenuates Disease Activity and Pro-inflammatory Cytokines Levels Insystemic Lupus Erythematosus Patients 2024 · Group II · Female patients with systemic lupus erythematosus (SLE); age not reported | 600 mg | — | 90 days | 15 |
| Randomised Clinical Trial Study: The Combination of Vitamin D and Curcumin Piperine Attenuates Disease Activity and Pro-inflammatory Cytokines Levels Insystemic Lupus Erythematosus Patients 2024 · Group III · Female patients with systemic lupus erythematosus (SLE); age not reported | 600 mg | 15.8 g | 90 days | 15 |
| Curcumin plus piperine improve body composition in patients with inflammatory bowel disease: a randomized, double-blind, placebo-controlled clinical trial 2025 · curcumin plus piperine · Adults aged 18 years or older with mild to moderate inflammatory bowel disease | 1 g | 10 mg | 12 weeks | — |
| Effects of Curcuminoids-Piperine Combination on Systemic Oxidative Stress, Clinical Symptoms and Quality of Life in Subjects with Chronic Pulmonary Complications Due to Sulfur Mustard: A Randomized Controlled Trial 2016 · curcuminoids + piperine combination · Adults with chronic pulmonary complications due to sulfur mustard exposure | 1.5 g | 15 mg | 4 weeks | 45 |
| Effects of curcumin supplementation on vitamin D levels in women with premenstrual syndrome and dysmenorrhea: a randomized controlled study 2022 · CUR group · Single women aged 18–24 with moderate to severe premenstrual syndrome and dysmenorrhea | 500 mg | 5 mg | 90 days | 38 |
| Increasing Post-Digestive Solubility of Curcumin Is the Most Successful Strategy to Improve its Oral Bioavailability: A Randomized Cross-Over Trial in Healthy Adults and In Vitro Bioaccessibility Experiments 2021 · Curcumin with adjuvants, including piperine · 12 healthy adults | 207 mg | — | 1 day | 12 |
| Antioxidant and anti-inflammatory effects of curcuminoid-piperine combination in subjects with metabolic syndrome: A randomized controlled trial and an updated meta-analysis 2015 · curcuminoids · Adults with metabolic syndrome diagnosed according to NCEP-ATPIII criteria | 1 g | 10 mg | 8 weeks | 59 |
| Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial 2014 · curcuminoids · Patients diagnosed with metabolic syndrome according to NCEP-ATPIII criteria and receiving standard of care | 1 g | — | 8 weeks | 50 |
| Curcuminoids Plus Piperine Modulate Adipokines in Type 2 Diabetes Mellitus 2017 · curcuminoids versus placebo group · Patients with type 2 diabetes; age and sex not reported | 1 g | 10 mg | 12 weeks | 50 |
| Effects of Curcuminoids Plus Piperine on Glycemic, Hepatic and Inflammatory Biomarkers in Patients with Type 2 Diabetes Mellitus: A Randomized Double-Blind Placebo-Controlled Trial 2018 · curcuminoids · Adults aged 18–65 with type 2 diabetes mellitus | 500 mg | 5 mg | 90 days | 50 |
| Effects of curcumin-piperine supplementation on systemic immunity in young women with premenstrual syndrome and dysmenorrhea: A randomized clinical trial 2022 · curcumin · Young women with premenstrual syndrome and primary dysmenorrhea | 500 mg | — | — | 40 |
| The Effects of Curcumin Plus Piperine Supplementation in Patients with Acute Myocardial Infarction: A Randomized, Double-Blind, and Placebo-Controlled Trial 2021 · active intervention group · Patients aged 18–75 years with acute myocardial infarction | 500 mg | — | 8 weeks | 38 |
| Effect of curcumin on inflammatory biomarkers and iron profile in patients with premenstrual syndrome and dysmenorrhea: A randomized controlled trial 2023 · Curcumin (CUR) group · Women aged 18–24 with moderate-to-severe premenstrual syndrome and dysmenorrhea | 500 mg | 5 mg | — | 38 |
| The effects of curcumin-piperine supplementation on inflammatory, oxidative stress and metabolic indices in patients with ischemic stroke in the rehabilitation phase: a randomized controlled trial 2023 · curcumin-piperine group · Adults aged 20–65 years with ischemic stroke in the rehabilitation phase, 3–6 months after the active stroke attack | 500 mg | 5 mg | 12 weeks | 33 |
| Therapeutic effects of curcumin and piperine combination in critically ill patients with sepsis: a randomized double-blind controlled trial 2025 · intervention group (curcumin-piperine) · Adults aged 20–75 with sepsis admitted to an ICU | 1 g | 10 mg | 7 days | 33 |
| Efficacy of curcumin plus piperine co-supplementation in moderate-to-high hepatic steatosis: A double-blind, randomized, placebo-controlled clinical trial 2023 · curcumin + piperine · Patients with moderate-to-high non-alcoholic fatty liver disease diagnosed by liver sonography; age and sex not specified | 500 mg | 5 mg | 12 weeks | 30 |
| Mitigation of Systemic Oxidative Stress by Curcuminoids in Osteoarthritis: Results of a Randomized Controlled Trial 2016 · curcuminoids group · Adults with mild-to-moderate primary knee osteoarthritis | 1.5 g | 15 mg | 6 weeks | 19 |
| Curcuminoids modify lipid profile in type 2 diabetes mellitus: A randomized controlled trial 2017 · curcuminoids · People with type 2 diabetes | 1 g | 10 mg | 12 weeks | — |
| Curcuminoids plus piperine improve nonalcoholic fatty liver disease: A clinical trial 2019 · curcuminoids plus piperine · Adults with ultrasound-determined nonalcoholic fatty liver disease; age and sex not specified | 500 mg | 5 mg | 12 weeks | — |
| Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial 2020 · curcuminoids group · Patients with non-alcoholic fatty liver disease (NAFLD); age and sex not reported | 500 mg | 5 mg | 8 weeks | — |
| Effects of supplementation with curcuminoids on serum adipokines in critically ill patients: a randomized double-blind placebo-controlled trial 2020 · Curcuminoids · Critically ill patients aged 18–65 years with traumatic brain injury | 500 mg | 5 mg | 7 days | — |
| Ubiquitin Proteasome System Activity is Suppressed by Curcumin following Exercise-Induced Muscle Damage in Human Skeletal Muscle 2021 · curcumin (CUR) group · Recreationally active males and females aged 18–30 | 2 g | 20 mg | 11 days | — |
| Evaluation of Curcumin-Piperine Supplementation in COVID-19 Patients Admitted to the Intensive Care: A Double-Blind, Randomized Controlled Trial 2023 · curcumin-piperine · Patients with COVID-19 admitted to the intensive care unit; age and sex not specified | 1.5 g | 15 mg | 7 days | — |
| Evaluation of the effectiveness of curcumin and piperine co-supplementation on inflammatory factors, cardiac biomarkers, atrial fibrillation, and clinical outcomes after coronary artery bypass graft surgery 2024 · Group B · Adults who underwent coronary artery bypass graft surgery | 500 mg | 5 mg | 5 days | — |
| Evaluation of the effectiveness of curcumin and piperine co-supplementation on inflammatory factors, cardiac biomarkers, atrial fibrillation, and clinical outcomes after coronary artery bypass graft surgery 2024 · Group C · Adults who underwent coronary artery bypass graft surgery | 1 g | 10 mg | 5 days | — |
| Evaluation of the effectiveness of curcumin and piperine co-supplementation on inflammatory factors, cardiac biomarkers, atrial fibrillation, and clinical outcomes after coronary artery bypass graft surgery 2024 · Group D · Adults who underwent coronary artery bypass graft surgery | 1.5 g | 15 mg | 5 days | — |
| Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial 2020 · Phytosomal curcumin · Adults aged 18–70 years with overweight (BMI 25–30 kg/m²) and suboptimal fasting plasma glucose (100–125 mg/dL) | 200 mg | 8 mg | 8 weeks | 40 |
| Curcumin and Piperine Combination for the Treatment of Patients with Non-alcoholic Fatty Liver Disease: A Double-Blind Randomized Placebo-Controlled Trial 2021 · curcumin group · Adults aged 18–65 with non-alcoholic fatty liver disease diagnosed by liver sonography | 500 mg | — | 60 days | 39 |
